Hideki Tomioka
Chief Scientific Officer, Member of the Board, Director of Research & Development FunPep
Seminars
Thursday 30th April 2026
Active Immunotherapy Using Universal Epitopes
1:30 pm
- Peptide vaccine technology involves prolonged suppression due to the production of anti-endogenous target protein antibody
- Peptide vaccines consist of highly immunogenic helper T cell epitope (AJP001) and B cell epitope originated from target protein
- Sharing the usefulness of antibody-inducing peptides based on non-clinical and clinical trial data of developed compounds
NEW COMPANY
